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ABSTRACT 
 
Background: We encountered a patient with positive anti-hepatitis C virus (HCV) whose serum 
HCV RNA was undetectable with the Roche AmpliPrep/Cobas TaqMan HCV Assay (CAP/CTM) 
version 1, but in high viral load with the Abbott RealTime HCV assay (ART). 
 
Methods: Discrepancies in the detectability of serum HCV RNA were investigated among 891 
consecutive patients who were positive for anti-HCV. Specific nucleotide variations causing the 
undetectability of HCV RNA were determined, and confirmed by synthesizing RNA coding those 
variations. Serum samples with the discrepancies were also reassessed by CAP/CTM version 2. 
 
Results: Among the 891 anti-HCV-positive patients, 4 patients had serum HCV RNA that was 
undetectable by CAP/CTM version 1 despite being >5 log IU/ml by ART. All four patients had 
HCV genotype 2a with high titers of anti-HCV. Sequencing of the HCV 5’ non-coding regions 
revealed 2 common variations: A at nt 145 and T at nt 151. Synthesized RNAs of the HCV 5’ 
non-coding region with standard (NCR145G151C) and variant nucleotides at nt 145 and nt 151 were 
quantified with CAP/CTM. RNAs of NCR145G151C and NCR145G151T were quantifiable with 
CAP/CTM version 1, while those of NCR145A151T and NCR145A151C went undetected. The 
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substitution from G to A at nt 145 specifically conferred this undetectability, while synthesized HCV 
RNA in correcting this variation will revert this undetectability. Reassessment of these samples by 
CAP/CTM version 2 resulted in similar levels of HCV RNA by ART.  
 
Conclusions: HCV patients with undetectable HCV RNA by CAP/CTM version 1, should be 
reassessed for viral quantification. 
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INTRODUCTION 
Hepatitis C virus (HCV) infection causes chronic hepatitis, liver cirrhosis, and hepatocellular 
carcinoma [1, 2]. More than 170 million people worldwide are infected with HCV, creating a serious 
global health problem. Monitoring of serum HCV RNA levels during antiviral therapy is essential 
for its management [3]. Sustained virological response is generally evaluated by whether HCV RNA 
can be detected in the serum 12 or 24 weeks after the cessation of the treatment. Recent monitoring 
of serum HCV RNA has mostly been done by real-time PCR methods, because real-time PCR 
methods are sensitive with low limits of detection, and have broad dynamic ranges of quantification 
[4, 5].  
The Roche AmpliPrep/Cobas TaqMan HCV Assay (CAP/CTM; Roche Molecular Systems, 
Pleasanton, CA) version 1 may underestimate or overestimate HCV RNA levels in a number of 
patients infected with HCV genotypes 2 and 4, because of mismatch of the primers or probes with 
the viral sequence [6]. The undetectability due to sequence mismatch in CAP/CTM version 1 has 
been overcome for the HCV genotype 4 by CAP/CTM version 2 [7]. The superiority of the Abbott 
RealTime HCV assay (ART; Abbott Molecular, Des Plaines, IL) or CAP/CTM version 2 to 
CAP/CTM version 1 in the sensitivity and accuracy has been also reported.  
The present study is the first to report on patients with HCV genotype 2a whose serum HCV RNA 
was undetectable with CAP/CTM version 1, despite a high viral load by ART. We clarified the cause 
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of the undetectability of HCV, and estimated the prevalence of this discrepancy among patients with 
positive results on the anti-HCV test. The serum samples with the discrepancies were also reassessed 
by CAP/CTM version 2, resulting in similar levels of HCV RNA by ART. 
 
 
METHODS 
Patients 
The present study enrolled consecutive patients who had positive results on the anti-HCV test 
(Lumipulse Presto Ortho HCV, Fujirebio, Tokyo, Japan), admitted for further examination or 
therapy for liver cirrhosis, esophageal and gastric varices, or hepatocellular carcinoma to the 
gastrointestinal unit of Okayama University Hospital between 2008 and 2012. Liver histology was 
evaluated according to the criteria of Desmet et al. [8]. HCV serogroup was assessed by the HCV 
serogrouping assay (HCV Gr, Sysmex International Reagents, Kobe, Japan), which can subgroup the 
patients in HCV serogroups 1 and 2, corresponding to HCV genotypes 1 and 2 respectively, with 
HCV group specific anti-non-structural region 4 antibodies. This assay is available not only for the 
patients with chronic HCV infection, but for those with resolved HCV. This study was performed in 
accordance with the Helsinki Declaration, and the protocol was approved by the ethics committee of 
the institute. This study was registered for University Hospital Medical Information Network 
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Clinical Trials Registry (UMIN 000001031). All patients provided informed consent before 
enrollment in the study.  
 
Quantification of HCV RNA 
Serum HCV RNA quantification was performed by RT-qPCR system of CAP/CTM version 1 with 
an automated sample preparation on the Cobas AmpliPrep extractor from 850 µL of serum, and the 
Cobas TaqMan 48 analyzer was used for automated real-time PCR amplification and the detection of 
PCR products, according to the manufacturer’s instructions. When the HCV RNA was undetectable, 
additional quantification of HCV RNA was done within a month by ART with serum samples stored 
at -80°C. The results of HCV RNA were also compared with the levels of HCV core antigens 
(Architect HCV Ag, Abbott, Tokyo, Japan), and the reassessed results of HCV RNA by CAP/CTM 
version 2.  
 
Analysis of sequence in the HCV 5’ non-coding region 
Serum RNA was extracted by means of a QIAamp Viral RNA Mini Kit according to the 
manufacturer’s protocol (Qiagen, Tokyo, Japan). HCV RNA was amplified by RT-PCR with 
primers corresponding to the HCV 5’ non-coding region for HCV genotype 2a as modified from the 
previous report [6]. The primers were 5’NCRS (5’-GGGCGACACTCCGCCATGAA-3’, nt 17 to 
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36) and 5’NCRAS (5’-CCCTGCGCGGCAACAAGTA-3’, nt 462 to 444). The first and second PCR 
rounds included an initial denaturation step at 95°C for 1 minute, followed by 30 cycles of 
denaturation at 95°C for 30 seconds, annealing at 52°C for 30 seconds, and elongation at 70°C for 
30 seconds, followed by a final elongation step at 70°C for 5 minutes. Direct sequencing was carried 
out by Big Dye termination cycle sequencing using an ABI Prism 310 genetic analyzer (Applied 
Biosystems, Foster City, CA).  
 
RNA synthesis of the HCV 5’ non-coding region 
Two vectors expressing the HCV 5’ non-coding region between nt 17 and 462 were constructed, 
whose sequences were identical except for G at nt 145 and C at nt 151 for NCR145G151C (the 
detectable standard), A at nt 145 and T at nt 151 for NCR145A151T, G at nt 145 and T at nt 151 for 
NCR145G151T, and A at nt 145 and C at nt 151 for NCR145A151C. NCR145A151T was the 
undetectable variant obtained from the serum of Patient 1. NCR145G151C, NCR145G151T, and 
NCR145A151C were constructed from NCR145A151T by PCR mutagenesis with primers 
containing base alterations. The PCR amplicons were cloned into pCR2.1 by means of a TA Cloning 
Kit according to the manufacturer’s protocol (Life Technologies, Tokyo, Japan). The sequences of 
these inserts were confirmed by Big Dye termination cycle sequencing (Applied Biosystems). The 
plasmids were utilized for RNA synthesis by means of a MEGAscript Kit according to the 
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manufacturer’s protocol (Life Technologies). Synthesized RNA was quantified with an automated 
sample preparation from 850 µL of the RNA sample by CAP/CTM version 1 and 500 µL of the 
RNA sample by CAP/CTM version 2 respectively on the Cobas TaqMan instruments, according to 
the manufacturer’s instructions. 
 
Immunohistochemistry of HCV core 
The presence of HCV core protein was assessed by immunohistochemistry. The liver tissues of the 
patients were fixed in 10% buffered formalin and embedded in paraffin. The sections were treated 
with citrate buffer (10mM citric acid, 0.05% Tween 20, pH 6.0) for 12 min at room temperature for 
antigen retrieval. The sections underwent a reaction with a monoclonal antibody for HCV core 
protein (CP-9; Institute of Immunology, Tokyo, Japan) after nonspecific binding was blocked with 
casein. The intrinsic peroxidase activity was blocked by immersing sections in a methanol solution 
containing 0.3% hydrogen peroxide. The Envision detection system was applied with DAB (Dako, 
CA, US). Two negative controls were applied: one without the first monoclonal antibody and the 
other from the HCV seronegative patients.  
 
 
Results 
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Our first patient in whom serum HCV RNA was undetectable with CAP/CTM version 1 
despite a high viral load with ART 
A male patient at forty-nine years of age (Patient 1) suffered from chronic hepatitis due to HCV 
genotype 2a with an abnormal level of alanine aminotransferase >100 IU/ml (Figure 1A). He 
received antiviral therapy of pegylated interferon and ribavirin. His therapeutic response was only 
partial, and his liver function test remained abnormal thereafter. Two years later, an abrupt decrease 
of serum HCV RNA was observed, and every 3 month-quantification with CAP/CTM version 1 for 
2 years detected no serum HCV RNA, although his level of alanine aminotransferase remained 
abnormal. Liver biopsy was performed for further examination for abnormal liver function test, 
revealing that his liver disease had advanced to liver cirrhosis with interface hepatitis (Figure 1B). 
The existence of HCV core antigens in both the serum (Table 1) and the liver (Figure 1C) was 
confirmed. Furthermore, reassessment of HCV RNA with ART showed a high viral load in his 
serum. 
 
Characteristics of patients with HCV RNA detectable by ART, but not by CAP/CTM 
Among the 891 consecutive patients with positive results on the anti-HCV test who were admitted to 
the gastrointestinal unit for liver related disorders due to HCV, CAP/CTM version 1 detected no 
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HCV RNA in 69; of these, 38 patients were sustained viral responders to previous interferon therapy, 
and 31 patients had not undergone antiviral therapies. Among those patients, 3 patients other than 
Patient 1 had serum HCV RNA >5 log IU/ml by HCV RNA quantification with ART (0.45 %). The 
characteristics of these patients are summarized in Table 1. All four patients were males in their 
forties or fifties. Three patients other than Patient 1 had not undergone antiviral therapies. Three had 
histological liver cirrhosis. They commonly had high titers of anti-HCV antibody and HCV genotype 
2a. Co-infection with hepatitis B virus or human immunodeficiency virus was ruled out. Although 
we doubted that some sustained viral responders might still have HCV because of false negative 
results by CAP/CTM version 1, serum HCV RNA was not detected by ART among the sustained 
viral responders. 
 
Comparison of sequences of the 5’ non-coding region of HCV 
We hypothesized that undetectable HCV RNA with CAP/CTM version 1 might occur due to the 
mismatch of the primers or probe with the sequence of the target regions. Therefore, the sequences 
of the HCV 5’ non-coding regions were determined by direct sequencing for all 4 patients whose 
HCV RNA was undetectable in the serum with CAP/CTM version 1, and their sequences were 
compared with the sequences of HCV genotypes 1a, 1b, 2a, 2b, and 3a using H77 as a reference 
(Figure 2). Their sequences commonly showed genotype 2a-specific features in the nt 218‒224, and 
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nt 240‒243 ranges, according to the report of the HCV genotyping [9, 10]. It is noteworthy that all 4 
patients had common variations of G to A at nt 145, C to T at nt 151, and G to A at nt 241. These 
variations are not seen in other sequences of various genotypes. Therefore, we synthesized RNAs 
coding the HCV 5’ non-coding region with different nucleosides at nt 145 and nt 151 (standard, 
NCR145G151C and variants, NCR145A151T, NCR145G151T, and NCR145A151C). The 
nucleoside type at nt 241 was A in the both RNAs, as the region around it commonly shows different 
sequences among the HCV genotypes [9]. The RNAs synthesized in various copy numbers/ml were 
quantified with CAP/CTM version 1. Synthesized RNAs of NCR145G151C and NCR145G151T at 
1010 copies/ml could be quantified as 3.9 Log IU/ml and 3.7 Log IU/ml respectively with CAP/CTM 
version 1, while the RNAs of NCR145A151T or NCR145A151C were undetectable. It was reported 
that the specific types of nucleoside at nt 107, nt 165, and nt 206 are associated with underestimation 
of HCV RNA levels as for HCV genotype 2 [6]. However, those features were not observed in the 
sequences of the present patients.  
 
Reassessment of serum HCV RNA by CAP/CTM version 2 
The levels of HCV RNA were also reassessed by CAP/CTM version 2 for the serum samples with 
discrepant quantification results. The samples resulted in equivalent levels of HCV RNA by both 
CAP/CTM version 2 and ART.  
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Analysis of nucleotide variation at nt 145 in the HCV 5’ non-coding region retrieved from the 
Genbank 
Total of 1090 HCV sequences were retrieved from the Genbank, exclusive of repetitive sequences, 
including 472 of genotype 1a, 466 of genotype 1b, 73 of genotype 2, 34 of genotype 4, and 3 of 
genotype 5. Nucleotide type at nt145 is G in most sequences and C in 17 sequences among HCV 
genotype 1a. Only one sequence among HCV genotype 1b had specific nucleotide variation type of 
A at nt 145. All the sequences among HCV genotypes 2 to 5 in the Genbank had G at nt 145.  
 
 
Discussion 
The present study is the first report of patients with HCV genotype 2a, in whom CAP/CTM version 
1 failed to detect HCV RNAs despite detection of a high viral load by ART. If such patients are 
erroneously considered to have spontaneous viral clearance, or autoimmune hepatitis with positive 
anti-HCV antibody, the opportunity of their receiving critical antiviral therapy will be lost. Occult 
HCV infection, defined as detection of HCV RNA in liver tissue or peripheral blood mononuclear 
cells with constantly undetectable serum HCV RNA [11], might involve such cases in whom HCV 
RNA is undetectable with CAP/CTM version 1. Reassessment of HCV RNA with ART or 
13 
 
quantification of HCV core antigen is desirable in cases in which HCV is not detected by CAP/CTM 
version 1. CAP/CTM version 2 is also helpful for the reassessment, if available. 
The present study investigated the characteristics of the patients whose serum HCV RNA was 
undetectable by CAP/CTM version 1. They were all male patients in their forties or fifties. We 
focused on the sequences of the HCV 5’ non-coding region, targeted by CAP/CTM and ART, and 
compared their sequences with those of the representative strains of HCV genotypes 1a, 1b, 2a, 2b, 
and 3a. It is noteworthy that they all had genotype 2a HCV and exhibited the same variations at nt 
145 and nt 151. Quantification of synthesized RNA with these specific variations at nt 145 and nt 
151 confirmed that the variation at nt 145 caused the undetectability of HCV RNA by CAP/CTM 
version 1.  
For searching the patient whose serum HCV RNA was undetectable by CAP/CTM version 1, the 
present study enrolled the consecutive patients who were positive for anti-HCV, admitted for further 
examination or therapy for liver related disorders. It was because these patients were supposed to 
suffer from chronic liver diseases due to HCV, although their HCV RNAs were not routinely 
assessed. Assuming from the genotype distribution among Japanese patients with chronic hepatitis C, 
two third of them might be infected with genotype 1b of HCV, one third with genotype 2, and a few 
with genotype 3. The present study had not determined the HCV genotypes of all the patients 
enrolled, and the frequency of these specific variations was 0.45% among those patients. By the 
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search in the Genbank, only one sequence of HCV genotype 1b had specific nucleotide variation 
type of A at nt 145 among the sequences of HCV genotypes 1 to 5 (0.092%), suggesting very low 
frequency of this specific variation. 
In conclusion, the present study reported on patients with HCV genotype 2a, whose serum HCV 
RNA was undetectable with CAP/CTM version 1 despite detection of a high viral load by ART. 
Specific nucleotide variation at nt 145 was found to be responsible for the undetectability of HCV 
RNA by CAP/CTM version 1. Reassessment of HCV RNA with ART or quantification of HCV core 
antigen is desirable in cases in which HCV is not detected by CAP/CTM version 1. CAP/CTM 
version 2 is also helpful for the reassessment if available. 
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Figure legends 
 
Figure 1: Clinical course and histology of Patient 1. 
The changes of serum HCV RNA and alanine aminotransferase are shown in Figure 1A. Liver 
histology indicates liver cirrhosis (Figure 1B, AZAN staining, 4-fold of original magnification). 
Immunohistochemical staining with a monoclonal antibody specific for HCV core demonstrates 
granular signal in the hepatocytes (Figure 1C, 400-fold of original magnification).  
 
Figure 2: Sequence alignment of HCV 5’ non-coding region of various HCV genotypes and the 
patients in this study. 
The sequence of HCV-H77 (accession# AF009606) was used as a reference; position numbers are 
given at the top. Dots indicate identical nucleosides. Sequence alignment of HCV 5’ non-coding 
regions contains genotype 1A of HCV-1 (M62321) and HCV-H (M67463), genotype 1B of HCV-J 
(D90208) and HCV-N (AF139594), genotype 2A of JCH-1 (AB047640), and HC-J6 (D00944), 
genotype 2B of HCV-MA (AB030907) and HCV-J8 (D10988), and genotype 3A of HCV-NZL1 
(D17763) and HCV-K3A (D28917). Sequences of Patients 1 to 4 are aligned at the bottom.  
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